[HTML][HTML] Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus–associated oropharynx squamous cell …
Journal of Clinical Oncology, 2019•ncbi.nlm.nih.gov
PURPOSE The purpose of this study was to determine if dose de-escalation from 60 to 66
Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human
papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain
historical rates for disease control while reducing toxicity and preserving swallow function
and quality of life (QOL).
Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human
papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain
historical rates for disease control while reducing toxicity and preserving swallow function
and quality of life (QOL).
Abstract
PURPOSE
The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma could maintain historical rates for disease control while reducing toxicity and preserving swallow function and quality of life (QOL).
ncbi.nlm.nih.gov